DBV Technologies Misses With Viaskin Peanut Allergy Patch

The French firm's share price nearly halved on disappointing Phase III data for Viaskin while those of its rival, Aimmune, shot up, but all hope for the patch product is not yet lost.

Peanut Butter Jelly Sandwich_1200 — No Jam Today but maybe Jam Tomorrow for Viaskin Peanut • Source: Shutterstock

DBV Technologies SA patch therapy for peanut allergy Viaskin Peanut missed the primary endpoint in its Phase III PETITES study, sending the company's share price down on NASDAQ by 46% to $25.95 on 23 Oct.

While the top-line results showed a significant response with a favorable tolerability profile, with 35.3% of patients responding to Viaskin...